Elranatamab-Based Triplet Effective in Transplant-Ineligible Myeloma

By News Health
2 hours Ago

(MedPage Today) — TORONTO — A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab (Elrexfio) was associated with high response rates and manageable toxicity in newly diagnosed, transplant…

Source link : https://www.medpagetoday.com/meetingcoverage/ims/117536

Author :

Publish date : 2025-09-18 21:03:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Psoriasis Patients Could Benefit From GLP-1 Therapy

Trump Administration Moves to Close 'Failing' Organ Donation Agency

Mounjaro Found Safe, Effective in Kids With Type 2 Diabetes

New Blood Tests for Early Cancer Detection Get Some Love From House Members

Starting HRT in early menopause may reduce women's risk of Alzheimer's

Texas Has a New Abortion Pill Law, but One Provider Plans to Keep Sending Them There